An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator

Trial Profile

An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator

Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Dovitinib (Primary) ; Fulvestrant
  • Indications Solid tumours
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 19 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 19 Nov 2016 This trial has been completed in Austria, according to European Clinical Trials Database record.
    • 05 Mar 2016 Planned End Date changed from 1 Jun 2017 to 1 Nov 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top